Table 4 Anticancer recombinant biopharmaceuticals approved until March 2015
From: Recombinant pharmaceuticals from microbial cells: a 2015 update
Drug name | Cell factory | Source | Biological role | Indications |
|---|---|---|---|---|
Denileukin diftitox | E. coli | Fusion protein | Diphtheria toxin fused to cytokine | Cutaneous T-cell lymphoma |
Endostatin | E. coli | Modified | Collagen derivative | Non-small cell lung cancer, metastatic colorectal cancer |
Aldesleukin | E. coli | Modified | Cytokine | Metastatic renal cell carcinoma, metastatic melanoma, kidney cancer, angiosarcoma |
Interleukin-2 | E. coli | Modified | Cytokine | Metastatic melanoma, metastatic renal cell carcinoma |
Filgrastim | E. coli | Modified | Cytokine | Acute lymphocytic leukaemia, solid tumour |
Interferon alpha-2a | E. coli | Modified | Cytokine | AIDS-related Kaposi’s sarcoma, follicular lymphoma, cutaneous T-cell lymphoma, melanoma, chronic myelocytic leukaemia, hairy cell leukaemia, renal cell carcinoma, kidney cancer |
Interferon alpha-2b | E. coli | Modified | Cytokine | AIDS-related Kaposi’s sarcoma, pancreatic endocrine tumour, melanoma, non-Hodgkin lymphoma, leukaemia, hairy cell leukaemia, renal cell carcinoma, multiple myeloma, CML, follicular lymphoma, melanoma |
Interferon alpha-1b | E. coli | Modified | Cytokine | Renal cell carcinoma, hairy cell leukaemia |
Interferon gamma-1a | E. coli | Modified | Cytokine | Kidney cancer, sezary syndrome, mycosis fungoides |
Tasonermin | E. coli | Natural | Cytokine | Soft tissue sarcoma |
Molgramostim | E. coli | Modified | Growth factor | Myelodysplastic syndrome |
Nartograstim | E. coli | Modified | Growth factor | Solid tumour |
Palifermin | E. coli | Fraction | Growth factor | Metastatic renal cell carcinoma, metastatic melanoma |
Sargramostim | S. cerevisiae | Modified | Growth factor | Acute myelocytic leukaemia |
Ziv-aflibercept | CHO cells | Fusion protein | Growth factor receptor fused to IgG1 | Metastatic colorectal cancer |
Thyrotropin alpha | CHO cells | Modified | Hormone | Thyroid cancer |
Trastuzumab biosimilar | CHO cells | Modified | Monoclonal antibody | Breast cancer, gastric cancer, metastatic breast cancer |
Rituximab biosimilar | CHO cells | Modified | Monoclonal antibody | Non-Hodgkin lymphoma, chronic lymphocytic leukaemia |
Interferon alpha | Human lymphoblastoid cells | Modified | Cytokine | AIDS-related Kaposi’s sarcoma, multiple myeloma, non-Hodgkin lymphoma, CML, hairy cell leukaemia, renal cell carcinoma |